{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:53:45Z","timestamp":1791312825038,"version":"4.3.1"},"reference-count":129,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013748","name":"Hope Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01CA178397-01"],"award-info":[{"award-number":["1R01CA178397-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R21CA205936-01"],"award-info":[{"award-number":["1R21CA205936-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007747","name":"University of Utah","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007747","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.hoc.2017.04.007","type":"journal-article","created":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T01:01:50Z","timestamp":1498870910000},"page":"589-612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":188,"title":["Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the\u00a0Development of Next Generation ABL Kinase Inhibitors"],"prefix":"10.1016","volume":"31","author":[{"given":"Ami B.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"O\u2019Hare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2017.04.007_bib1","unstructured":"SEER cancer statistics factsheets: chronic myeloid leukemia. Bethesda (MD): National Cancer Institute. Available at: http:\/\/seer.cancer.gov\/statfacts\/html\/cmyl.html. Accessed November 17, 2016."},{"key":"10.1016\/j.hoc.2017.04.007_bib2","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.hoc.2017.04.007_bib3","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2017.04.007_bib4","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.007_bib5","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib6","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.6004\/jnccn.2014.0159","article-title":"Chronic myelogenous leukemia, version 1.2015","volume":"12","author":"O'Brien","year":"2014","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.hoc.2017.04.007_bib7","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1158\/1078-0432.CCR-07-1112","article-title":"A\u00a0half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response","volume":"13","author":"Press","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"Suppl 10","key":"10.1016\/j.hoc.2017.04.007_bib8","doi-asserted-by":"crossref","first-page":"x274","DOI":"10.1093\/annonc\/mdl273","article-title":"Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors","volume":"17","author":"Hochhaus","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2017.04.007_bib9","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.chembiol.2013.06.001","article-title":"Ins and outs of kinase DFG motifs","volume":"20","author":"Treiber","year":"2013","journal-title":"Chem Biol"},{"key":"10.1016\/j.hoc.2017.04.007_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting cancer with small molecule kinase inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.hoc.2017.04.007_bib11","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.hoc.2017.04.007_bib12","doi-asserted-by":"crossref","first-page":"18292","DOI":"10.1074\/jbc.M801337200","article-title":"Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib\/nilotinib and dasatinib","volume":"283","author":"Vajpai","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.hoc.2017.04.007_bib13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2017.04.007_bib14","doi-asserted-by":"crossref","first-page":"e29828","DOI":"10.1371\/journal.pone.0029828","article-title":"Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain","volume":"7","author":"Levinson","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.hoc.2017.04.007_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1747-0285.2010.01054.x","article-title":"Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance","volume":"77","author":"Zhou","year":"2011","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.hoc.2017.04.007_bib16","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.hoc.2017.04.007_bib17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2017.04.007_bib18","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib19","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.007_bib20","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.leu.2402889","article-title":"Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back","volume":"17","author":"von Bubnoff","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.007_bib21","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2017.04.007_bib22","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2017.04.007_bib23","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V100.3.1014","article-title":"Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment","volume":"100","author":"Roche-Lestienne","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib24","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","article-title":"High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy","volume":"106","author":"Willis","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib25","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib26","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia","volume":"12","author":"O'Hare","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.hoc.2017.04.007_bib27","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2017.04.007_bib28","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.hoc.2017.04.007_bib29","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s11899-015-0248-3","article-title":"Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors","volume":"10","author":"Eide","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.hoc.2017.04.007_bib30","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","article-title":"AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL","volume":"94","author":"Weisberg","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.hoc.2017.04.007_bib31","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/leu.2009.193","article-title":"Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history","volume":"24","author":"Jabbour","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.007_bib32","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2017.04.007_bib33","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2017.04.007_bib34","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1182\/blood-2015-08-660977","article-title":"Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients","volume":"127","author":"Deininger","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib35","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1158\/0008-5472.CAN-05-0076","article-title":"Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia","volume":"65","author":"Barnes","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2017.04.007_bib36","doi-asserted-by":"crossref","first-page":"5411","DOI":"10.1182\/blood-2006-06-032490","article-title":"Role of BCR\/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells","volume":"109","author":"Modi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib37","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","article-title":"Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia","volume":"15","author":"Milojkovic","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2017.04.007_bib38","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","article-title":"Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib","volume":"28","author":"White","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2017.04.007_bib39","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib40","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3324\/haematol.2011.056457","article-title":"Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib","volume":"97","author":"White","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2017.04.007_bib41","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in\u00a0vitro sensitivity to imatinib","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib42","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-07-5095","article-title":"Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications","volume":"14","author":"Hiwase","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2017.04.007_bib43","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1038\/leu.2015.35","article-title":"Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells","volume":"29","author":"Lu","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.007_bib44","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/clpt.2013.208","article-title":"Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib","volume":"95","author":"Eadie","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.hoc.2017.04.007_bib45","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1158\/1535-7163.MCT-12-0302","article-title":"The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2","volume":"11","author":"Sen","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.hoc.2017.04.007_bib46","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/leu.2016.179","article-title":"The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment","volume":"31","author":"Eadie","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.007_bib47","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/leu.2014.38","article-title":"The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia","volume":"28","author":"Giannoudis","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.007_bib48","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/leu.2014.6","article-title":"MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure","volume":"28","author":"Agrawal","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.007_bib49","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12032-010-9456-9","article-title":"Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia","volume":"28","author":"Ni","year":"2011","journal-title":"Med Oncol"},{"key":"10.1016\/j.hoc.2017.04.007_bib50","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood-2008-03-147744","article-title":"Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"112","author":"Dulucq","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib51","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","article-title":"Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib","volume":"117","author":"Haouala","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib52","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00280-011-1797-3","article-title":"Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients","volume":"69","author":"Takahashi","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.hoc.2017.04.007_bib53","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1177\/0091270009333854","article-title":"Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects","volume":"49","author":"Eley","year":"2009","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.hoc.2017.04.007_bib54","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/leu.2016.51","article-title":"A\u00a0role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia","volume":"30","author":"Wagle","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.007_bib55","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1038\/leu.2015.196","article-title":"Beta-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"29","author":"Eiring","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.007_bib56","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/leusup.2014.3","article-title":"STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia","volume":"3","author":"Eiring","year":"2014","journal-title":"Leuk Suppl"},{"key":"10.1016\/j.hoc.2017.04.007_bib57","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/leu.2011.325","article-title":"Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors","volume":"26","author":"Traer","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.007_bib58","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1158\/1535-7163.MCT-08-0314","article-title":"Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance","volume":"7","author":"Bewry","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.hoc.2017.04.007_bib59","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood.V86.2.726.bloodjournal862726","article-title":"Phosphatidylinositol-3 kinase activity is regulated by BCR\/ABL and is required for the growth of Philadelphia chromosome-positive cells","volume":"86","author":"Skorski","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib60","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/sj.leu.2403898","article-title":"Compensatory PI3-kinase\/Akt\/mTor activation regulates imatinib resistance development","volume":"19","author":"Burchert","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.007_bib61","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4161\/cbt.26725","article-title":"Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation","volume":"15","author":"Okabe","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.hoc.2017.04.007_bib62","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood-2003-04-1271","article-title":"BCR\/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells","volume":"103","author":"Chu","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib63","doi-asserted-by":"crossref","first-page":"252ra121","DOI":"10.1126\/scitranslmed.3009073","article-title":"A\u00a0therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia","volume":"6","author":"Ma","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.hoc.2017.04.007_bib64","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ccr.2011.11.004","article-title":"Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia","volume":"20","author":"Packer","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2017.04.007_bib65","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1158\/2159-8290.CD-13-0235","article-title":"MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction","volume":"4","author":"Asmussen","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.hoc.2017.04.007_bib66","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1182\/blood-2014-08-588855","article-title":"shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance","volume":"125","author":"Khorashad","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib67","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1182\/blood-2013-04-495374","article-title":"Preclinical and clinical efficacy of XPO1\/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias","volume":"122","author":"Walker","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2017.04.007_bib68","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-16-0263","article-title":"Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition","volume":"6","author":"Scott","year":"2016","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.hoc.2017.04.007_bib69","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/2159-8290.CD-15-1439","article-title":"Chronic myelogenous leukemia initiating cells require Polycomb group protein EZH2","volume":"6","author":"Xie","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.hoc.2017.04.007_bib70","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1182\/blood-2012-02-412890","article-title":"Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin signaling","volume":"121","author":"Zhang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib71","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1756-8722-3-33","article-title":"Role of Wnt canonical pathway in hematological malignancies","volume":"3","author":"Ge","year":"2010","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.hoc.2017.04.007_bib72","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","article-title":"Loss of beta-catenin impairs the renewal of normal and CML stem cells in\u00a0vivo","volume":"12","author":"Zhao","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2017.04.007_bib73","doi-asserted-by":"crossref","first-page":"E2298","DOI":"10.1073\/pnas.1301838110","article-title":"Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function","volume":"110","author":"Lim","year":"2013","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2017.04.007_bib74","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1182\/blood-2007-08-109330","article-title":"Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells","volume":"111","author":"Wu","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib75","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djn188","article-title":"Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase","volume":"100","author":"Wu","year":"2008","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.hoc.2017.04.007_bib76","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib77","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/jnci\/djn204","article-title":"Persistent LYN signaling in imatinib-resistant, BCR-ABL-independent chronic myelogenous leukemia","volume":"100","author":"O'Hare","year":"2008","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.hoc.2017.04.007_bib78","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1182\/blood-2013-07-511907","article-title":"Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition","volume":"123","author":"Ng","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib79","doi-asserted-by":"crossref","first-page":"25476","DOI":"10.1038\/srep25476","article-title":"Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia","volume":"6","author":"Irvine","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.hoc.2017.04.007_bib80","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1158\/1078-0432.CCR-13-3317","article-title":"Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells","volume":"21","author":"Wu","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2017.04.007_bib81","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2013-07-517847","article-title":"The IL-2\/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells","volume":"123","author":"Kobayashi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib82","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1172\/JCI66129","article-title":"Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival","volume":"124","author":"Chen","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.hoc.2017.04.007_bib83","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood.V126.23.51.51","article-title":"Knockdown (KD) of Mir-126 expression enhances tyrosine kinase inhibitor (TKI)-mediated targeting of chronic myelogenous leukemia (CML) stem cells","volume":"126","author":"Zhang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib84","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccr.2008.08.003","article-title":"Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation","volume":"14","author":"Dierks","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2017.04.007_bib85","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/ng.389","article-title":"Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia","volume":"41","author":"Chen","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.hoc.2017.04.007_bib86","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1172\/JCI68951","article-title":"PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells","volume":"123","author":"Neviani","year":"2013","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.hoc.2017.04.007_bib87","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-05-501072","article-title":"Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile","volume":"122","author":"Cramer-Morales","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib88","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood-2006-10-054098","article-title":"Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells","volume":"110","author":"Peng","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib89","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","article-title":"Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib","volume":"21","author":"Li","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2017.04.007_bib90","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI35660","article-title":"Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells","volume":"119","author":"Bellodi","year":"2009","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.hoc.2017.04.007_bib91","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/nature07016","article-title":"PML targeting eradicates quiescent leukaemia-initiating cells","volume":"453","author":"Ito","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2017.04.007_bib92","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/leu.2016.66","article-title":"The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia","volume":"30","author":"Huang","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.007_bib93","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1073\/pnas.1213021110","article-title":"ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia","volume":"110","author":"Jiang","year":"2013","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2017.04.007_bib94","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ccr.2013.01.025","article-title":"Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression","volume":"23","author":"Reavie","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2017.04.007_bib95","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nature18288","article-title":"Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells","volume":"534","author":"Abraham","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2017.04.007_bib96","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1084\/jem.20110304","article-title":"BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia","volume":"208","author":"Hurtz","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.hoc.2017.04.007_bib97","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1172\/JCI31095","article-title":"FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia","volume":"117","author":"Neviani","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.hoc.2017.04.007_bib98","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.stem.2012.12.011","article-title":"A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition","volume":"12","author":"Goff","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.hoc.2017.04.007_bib99","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1182\/blood.V124.21.398.398","article-title":"ABL001, a potent allosteric inhibitor of BCR-ABL, prevents emergence of resistant disease when administered in combination with nilotinib in an in\u00a0vivo murine model of chronic myeloid leukemia","volume":"124","author":"Wylie","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib100","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood.V126.23.138.138","article-title":"ABL001, a potent, allosteric inhibitor of BCR-ABL, exhibits safety and promising single- agent activity in a phase I study of patients with CML with failure of prior TKI therapy","volume":"126","author":"Ottmann","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib101","doi-asserted-by":"crossref","first-page":"B78","DOI":"10.1158\/1538-7445.TIM2013-B78","article-title":"Abstract B78: rebastinib, a small molecule TIE2 kinase inhibitor, prevents primary tumor growth and lung metastasis in the PyMT breast cancer model","volume":"73","author":"Smith","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2017.04.007_bib102","first-page":"1450","article-title":"Bafetinib, a dual Bcr-Abl\/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia","volume":"11","author":"Santos","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.hoc.2017.04.007_bib103","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3324\/haematol.2014.115279","volume":"100","author":"Borthakur","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2017.04.007_bib104","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/leu.2015.318","article-title":"Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia","volume":"30","author":"Zabriskie","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.007_bib105","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature14119","article-title":"Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation","volume":"519","author":"Pemovska","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2017.04.007_bib106","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1182\/blood.V126.23.476.476","article-title":"Efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia patients: 12\u00a0months result of phase 3 clinical trial","volume":"126","author":"Kwak","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib107","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1038\/leu.2015.42","article-title":"Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1","volume":"29","author":"Zabriskie","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.007_bib108","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.clml.2016.06.012","article-title":"Discontinuing tyrosine kinase inhibitor therapy in chronic myelogenous leukemia: current understanding and future directions","volume":"16","author":"Bhalla","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"10.1016\/j.hoc.2017.04.007_bib109","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2016.115","article-title":"The concept of treatment-free remission in chronic myeloid leukemia","volume":"30","author":"Saussele","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.007_bib110","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/leu.2012.313","article-title":"Re-emergence of interferon-alpha in the treatment of chronic myeloid leukemia","volume":"27","author":"Talpaz","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.007_bib111","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon Alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2017.04.007_bib112","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","article-title":"Combination of pegylated IFN-\u03b12b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia","volume":"118","author":"Simonsson","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib113","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.007_bib114","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/leu.2016.121","article-title":"Safety and efficacy of the combination of pegylated interferon-alpha2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients","volume":"30","author":"Hjorth-Hansen","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2017.04.007_bib115","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2352-3026(14)00027-1","article-title":"Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study","volume":"2","author":"Nicolini","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.hoc.2017.04.007_bib116","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1182\/blood.V126.23.134.134","article-title":"Combination of dasatinib and peg-interferon alpha 2b in chronic phase chronic myeloid leukemia (CP-CML) first line: preliminary results of a phase II trial, from the French Intergroup of CML (Fi-LMC)","volume":"126","author":"Roy","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib117","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1182\/blood.V124.21.152.152","article-title":"Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION, CA180-056)","volume":"124","author":"Cortes","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib118","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood.V95.5.1781.005k46_1781_1787","article-title":"Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses","volume":"95","author":"Pinilla-Ibarz","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib119","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)17945-8","article-title":"Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial","volume":"365","author":"Bocchia","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2017.04.007_bib120","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/79526","article-title":"Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia","volume":"6","author":"Molldrem","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2017.04.007_bib121","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3324\/haematol.2010.031674","article-title":"Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T\u00a0cells in myeloid malignancies","volume":"96","author":"Rezvani","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2017.04.007_bib122","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1182\/blood.V95.7.2198","article-title":"Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1","volume":"95","author":"Gao","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib123","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1182\/blood-2014-01-549022","article-title":"A\u00a0TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias","volume":"123","author":"Dubrovsky","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib124","doi-asserted-by":"crossref","first-page":"16280","DOI":"10.1073\/pnas.1004408107","article-title":"Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein","volume":"107","author":"J\u00e4r\u00e5s","year":"2010","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2017.04.007_bib125","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/bjh.12978","article-title":"SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia","volume":"166","author":"Frolova","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2017.04.007_bib126","doi-asserted-by":"crossref","first-page":"8637","DOI":"10.18632\/oncotarget.2353","article-title":"Selective JAK2\/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem\/progenitor cells","volume":"5","author":"Lin","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.hoc.2017.04.007_bib127","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2013-12-545640","article-title":"JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in\u00a0vitro and in\u00a0vivo","volume":"124","author":"Gallipoli","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2017.04.007_bib128","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature15248","article-title":"Erosion of the chronic myeloid leukaemia stem cell pool by PPARgamma agonists","volume":"525","author":"Prost","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2017.04.007_bib129","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858817300643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858817300643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:04:28Z","timestamp":1760184268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858817300643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":129,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0889858817300643"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2017.04.007","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the\u00a0Development of Next Generation ABL Kinase Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2017.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}